5 of the initial 12 undertreated patients were dropped from trial before ever getting a second treatment. Of the 7 remaining patients from the initial 12, only 4 got a second treatment which was optimized.
Toronto, Ontario – September 24, 2020, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDC”) and associated drug formulations, announced today that McGill University Health Centre (“MUHC”) has re-commenced new patient enrollment and treatment in the Company’s Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”).
Study II has enrolled and treated 12 patients to date. Out of the 7 patients that are eligible to receive the second treatment, 5 have been treated and 2 are pending. 2 out of the last 5 patients treated for the second time have been treated with the optimized Study II treatment, which will also be the case for the 2 patients that are pending their second treatment."